Metagenomics Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product and Service (Reagents & consumables, Instruments, Services), By Technology (Shotgun metagenomic sequencing, 16S rRNA sequencing, Whole genome sequencing & de novo assembly, Meta transcriptomics), By Application (Drug discovery, Ecological & environmental metagenomics, Clinical diagnostics, Biofuel, Industrial applications), By Region and Competition, 2020-2030F

Market Overview

Global Metagenomics Sequencing Market was valued at USD 2.89 billion in 2024 and is expected to reach USD 6.47 billion by 2030 with a CAGR of 14.38% during the forecast period. Metagenomics Sequencing Market is expected to witness impressive growth during the forecast period. This can be ascribed to the growing awareness about genetic disorders due to genetic history along with growing demand for advanced bioinformatics tools. Also, growing development of novel drugs and high throughput screening methods along with cost effective technologies developments are expected to create lucrative growth during the forecast period. Similarly, rise in research and development activities for identifying newer antibiotics and enzymes is a major factor fueling the growth of market over the upcoming years. For instance, in August 2022, OpGen, Inc., a personalized medicine company, announced to launch next-generation sequencing (NGS) services under the subsidiary, Ares Genetics.

Key Market Drivers

Technological Advancements in Next-Generation Sequencing (NGS)

The rapid evolution of Next-Generation Sequencing (NGS) technologies has significantly propelled the metagenomic sequencing market. Modern NGS platforms offer high-throughput, cost-effective, and accurate sequencing capabilities, enabling comprehensive analysis of complex microbial communities. This technological progress has facilitated the identification of novel microorganisms, understanding of microbial interactions, and exploration of microbial roles in various ecosystems. Government initiatives have played a pivotal role in supporting these advancements. For instance, the U.S. government announced a substantial funding of US$ 515 million for the Human Microbiome Project in 2019, aiming to enhance the understanding of microbial communities and their impact on human health. Such investments have not only accelerated research but also fostered collaborations between public institutions and private entities, further driving innovation in the field. Moreover, the decreasing cost of sequencing has made these technologies more accessible. The cost of sequencing a human genome has plummeted from over US$ 100 million in 2001 to approximately US$ 600–1,000 per genome, thanks to advancements by companies like Illumina and Oxford Nanopore. This affordability has expanded the adoption of metagenomic sequencing in research and clinical applications, contributing to market growth

Rising Prevalence of Infectious Diseases

The increasing incidence of infectious diseases globally has underscored the importance of metagenomic sequencing in pathogen detection and outbreak surveillance. Metagenomic approaches allow for the unbiased identification of pathogens directly from clinical samples, facilitating timely diagnosis and management of infectious diseases. According to UNAIDS, the number of people living with HIV surpassed 39 million globally in July 2023, marking a 3.17% increase from 2020. Additionally, the Centers for Disease Control and Prevention (CDC) reported a 5.9% increase in tuberculosis (TB) cases in the U.S., from 7,874 in 2021 to 8,331 in 2022. These statistics highlight the escalating burden of infectious diseases and the consequent demand for advanced diagnostic tools like metagenomic sequencing.

Government and private sector collaborations have further bolstered this driver. For example, the Chan Zuckerberg Initiative (CZI), in partnership with the Bill & Melinda Gates Foundation, announced a US$ 2 million grant to support metagenomics research in low- and middle-income countries, enhancing access to NGS technologies and bioinformatics training.

Download Free Sample Report

Key Market Challenges

High Cost of Sequencing Equipment and Budget Constraints

Despite the decreasing cost of sequencing per genome, the initial investment required for high-throughput sequencing platforms remains substantial. For instance, Illumina's NovaSeq 5000 and 6000 systems are priced at approximately US$ 850,000 and US$ 985,000, respectively. Such costs are prohibitive for many research institutions, particularly in developing countries, where academic R&D is heavily reliant on external funding.

Budget constraints limit the acquisition and utilization of advanced sequencing technologies, hindering the expansion of metagenomic research. While government and private entities continue to offer financing for research, the high capital expenditure associated with sequencing equipment poses a significant barrier to market growth. Addressing this challenge requires concerted efforts to reduce equipment costs, provide financial assistance, and develop cost-effective sequencing solutions tailored for resource-limited settings.

Data Management and Standardization Issues

The massive datasets generated by metagenomic sequencing pose challenges in terms of storage, analysis, and interpretation. Moreover, the lack of standardized protocols for sample collection, sequencing, and data processing leads to inconsistencies, making it difficult to compare results across studies.

This lack of standardization hampers collaborative research efforts and the reproducibility of findings. To address these issues, there is a need for the development of universal guidelines and robust bioinformatics tools that can handle diverse datasets efficiently. Government and academic institutions are encouraged to invest in training programs and infrastructure development to build capacity in bioinformatics and data management.

Key Market Trends

Integration of Artificial Intelligence (AI) and Machine Learning (ML) in Data Analysis

The integration of AI and ML technologies into metagenomic data analysis is revolutionizing the field by enabling faster and more accurate interpretation of complex datasets. These technologies facilitate the identification of patterns and relationships within massive amounts of sequencing data, leading to novel insights into microbial community structures and functions.

For instance, ML algorithms are being developed to predict antibiotic resistance genes from metagenomic data, enhancing the applicability of metagenomics in therapeutic contexts. Furthermore, AI-powered analysis accelerates environmental monitoring and pathogen identification, making metagenomic sequencing more accessible and actionable for researchers and clinicians. The adoption of AI and ML in metagenomics is supported by government initiatives aimed at advancing bioinformatics capabilities. Investments in computational infrastructure and training programs are essential to harness the full potential of these technologies in metagenomic research and applications.

Increased Focus on Microbiome Research

There is a growing recognition of the microbiome's impact on human health, agriculture, and environmental sustainability, leading to an increased focus on microbiome research. Metagenomic sequencing plays a crucial role in this research by enabling comprehensive analysis of microbial communities and their functions.

In healthcare, understanding the human microbiome has implications for disease prevention, diagnosis, and treatment. In agriculture, soil microbiome studies inform sustainable farming practices and crop productivity. Environmental applications include monitoring ecosystem health and assessing the impact of pollutants. Government agencies and research institutions are investing in microbiome projects to explore these applications. For example, the U.S. National Institutes of Health (NIH) has supported various microbiome initiatives, emphasizing the importance of microbial research in advancing public health and environmental stewardship.

Segmental Insights

Product and Service Insights

Based on Product and Service, the reagents and consumables category held the largest share in the Global Metagenomic Sequencing Market. This dominance is largely attributed to the recurring need for these products in every sequencing workflow, including sample preparation, library construction, and amplification processes. Reagents and consumables are essential components in conducting high throughput metagenomic studies, and their continual usage across multiple stages of research and diagnostic procedures contributes significantly to their high demand.

Moreover, as sequencing platforms evolve to deliver more accurate and faster results, the need for high-quality, compatible reagents and consumables also rises. Many of these consumables are designed specifically for use with platforms, which encourages repeated purchases and locks in users to vendors, further enhancing the category's market performance. Additionally, increased adoption of metagenomics in fields such as clinical diagnostics, environmental microbiology, and agricultural research has led to a corresponding rise in reagent usage.

Download Free Sample Report

Regional Insights

Based on the region, North America held the largest share in the global metagenomic sequencing market, driven by a combination of advanced healthcare infrastructure, robust research and development activities, and strong governmental and institutional support. The United States has been a frontrunner in genomic and microbiome research due to significant investments from both public and private sectors. Prominent research institutions, academic centers, and biotech companies in North America are at the forefront of innovations in sequencing technologies, including metagenomics. Moreover, government initiatives such as the Human Microbiome Project by the U.S. National Institutes of Health (NIH) have played a critical role in the development and expansion of the metagenomics field. This project, which started in 2007, aimed to characterize the microbial communities found at multiple human body sites and to analyze their role in human health and disease. These kinds of projects have laid a strong foundation for subsequent clinical and environmental metagenomic applications.

Recent Developments

• In March 2024, Tiny Health, a company specializing in at-home gut microbiome testing for infants, secured a Series A funding round of USD 8.5 million. This investment is aimed at advancing innovation in gut health and strengthening the company’s research and development efforts, particularly to help address the growing crisis of chronic conditions among children.
• In January 2024, the U.K. announced a new Strategic Dialogue on Biological Security with the U.S. to protect from increased biological threats.
• In November 2023, QIAGEN introduced the Microbiome WGS SeqSets, a comprehensive workflow solution tailored for microbiome research. This new product streamlines the entire process from sample preparation to data analysis, offering researchers a user-friendly system that enhances both efficiency and reproducibility in whole genome sequencing of microbiomes.
• In January 2023, QIAGEN announced closing the acquisition of Verogen, using GS technology for forensic and human identification to advance the future of Human Identification (HID) and forensics.
• In March 2023, Illumina, Inc. launched its first-of-its-kind product, Illumina Complete Long Read technology. Technology enables short-read and long-read in a single instrument.

Key Market Players

• BGI Genomics Co Ltd.
• Eurofins Scientific SE
• Illumina Inc.
• Macrogen, Inc.
• Oxford Nanopore Technologies plc.
• Pacific Biosciences of California, Inc.
• PerkinElmer Inc.
• QIAGEN N.V.
• Swift Biosciences Inc.
• Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Metagenomics Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Metagenomics Sequencing Market, By Product and Service:

o   Reagents & consumable

o   Instruments

o   Services

• Metagenomics Sequencing Market, By Technology:

o   Shotgun metagenomic sequencing

o   16S rRNA sequencing

o   Whole genome sequencing & de novo assembly

o   Meta transcriptomics

• Metagenomics Sequencing Market, By Application:

o   Drug discovery

o   Ecological & environmental metagenomics

o   Clinical diagnostics

o   Biofuel

o   Industrial applications

• Metagenomics Sequencing Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Metagenomics Sequencing Market.

Available Customizations:

Global Metagenomics Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Metagenomics Sequencing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]